A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin’s Lymphoma (RATE)
Condition(s):Non-Hodgkin’s LymphomaLast Updated:May 15, 2017Completed
Hide Studies Not Open or Pending
Condition(s):Non-Hodgkin’s LymphomaLast Updated:May 15, 2017Completed
Condition(s):MiscarriageLast Updated:October 22, 2021Unknown status
Condition(s):MiscarriageLast Updated:October 26, 2021Unknown status
Condition(s):MiscarriageLast Updated:November 2, 2021Unknown status
Condition(s):Refractory Idiopathic Aplastic Anemia; Haploidentical Allogeneic Hematopoietic Stem Cell TransplantationLast Updated:November 24, 2023Recruiting
Condition(s):COVID-19Last Updated:February 20, 2024Terminated
Condition(s):FeverLast Updated:September 21, 2005Completed
Condition(s):Covid19Last Updated:April 20, 2021Completed
Condition(s):Covid19Last Updated:August 20, 2021Unknown status
Condition(s):COVID-19; Favipiravir (Favipira)Last Updated:May 26, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.